Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. In vitro data suggest that mesna is a substrate of the OAT1, OAT3 and OAT4 renal transporters. A clinically significant interaction with emtricitabine is unlikely. However, tenofovir may compete for active transporters during renal elimination, in particular OAT1 which may raise exposure of mesna and/or tenofovir. Administration of probenecid (an OAT inhibitor) to healthy subjects significantly increased combined mesna and mesna disulphide plasma exposure, while decreasing the renal clearance. This may decrease the efficacy of mesna as a chemoprotectant, increasing the risk of ifosfamide- and cisplatin-induced toxicities.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking